Amuvatinib (MP-470) is a potent RTK inhibitor that effectively inhibits c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively.
Amuvatinib (MP-470) also inhibits several mutants of c-Kit and Axl.
Amuvatinib (MP-470) inhibits prostate cancer cell proliferation (IC50=4-8 uM), promotes cell cycle arrest and apoptosis.
Amuvatinib (MP-470) completely inhibites phosphorylation of the HER members (HER1, 2, 3), binding of PI3K regulatory unit p85 to HER3 and downstream Akt activity in combination with Erlotinib.
Amuvatinib (MP-470) exhibits synergistic effect in LNCaP mouse xenograft model.
